Martin Mackay, Ph.D. has been named president of R&D at AstraZeneca. He will lead the company’s R&D organization and will have overall accountability for new products — both small molecules and biologics — from AZ’s pipeline. He will start his new role on July 1, 2010 and will be based at the company’s headquarters in London. Dr. Mackay joined AstraZeneca from Pfizer, where he served as president, PharmaTherapeutics R&D, and was a member of the Pfizer Executive Leadership ...